Industry News
Antibody-Oligonucleotide Conjugates (AOCs…
Antibody–Oligonucleotide Conjugate (AOC) technology has emerged as a promising strategy. By leveraging the tissue-specific binding affinity of monoclonal antibodies or their functional fragm…
Monodisperse PEG in Modern Drug Developme…
Learn how monodisperse PEG improves drug precision, safety, and consistency in ADCs, peptides, and FDA-approved therapies.
2025 FDA Drug Approvals: A Landmark Year …
With 46 new drug approvals, the agency stayed right on track with its usual pace, but the real story is in what they approved.
In Vivo CAR-T Cell Therapy: Current Strat…
This article reviews in vivo CAR-T approaches, delivery vectors, clinical pipelines, and how the field is evolving beyond ex vivo CAR-T.
Therapeutic Advances in Hemophilia Manage…
Hemophilia is a rare, inherited bleeding disorder, most commonly affecting males, that is characterized by a deficiency in blood clotting. The two most common severe forms are hemophilia A, c…
Next-Generation Radiopharmaceuticals: Ins…
In 2018 and 2022, Novartis achieved regulatory approval for two landmark radionuclide drug conjugates (RDCs), Lutathera and Pluvicto, marking the entry of radiopharmaceuticals into a phase of…
Long-Acting FGF21 Therapies for MASH
The FGF21 pathway offers therapeutic potential that goes beyond single-mechanism drugs in the MASH field. Long-acting engineering strategies have largely overcome the developability challenge…
Oligonucleotide Drug Delivery: Advances a…
Learn how GalNAc, LNP, AOC, CPP, and exosome-based systems are reshaping oligonucleotide drug delivery for precise, tissue-targeted therapies.
Tetrahydrocurcumin and its Therapeutic Po…
Tetrahydrocurcumin (THC), a major color-free metabolite of curcumin formed by reducing its central double bonds, displays better bioavailability and different biological activity and molecula…
CLDN18.2-Targeted ADCs: A Promising Break…
As of 2025, the global R&D landscape for CLDN18.2-targeted antibody-drug conjugates (ADCs) is expanding rapidly, with multiple candidates entering mid- to late-stage clinical trials.
sales@huatengusa.com
+86 0731 89916275